Wall Street brokerages expect Interpace Diagnostics Group Inc (NASDAQ:IDXG) to announce ($0.07) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Interpace Diagnostics Group’s earnings, with the lowest EPS estimate coming in at ($0.07) and the highest estimate coming in at ($0.06). Interpace Diagnostics Group reported earnings per share of ($0.15) during the same quarter last year, which suggests a positive year over year growth rate of 53.3%. The company is scheduled to report its next quarterly earnings results on Monday, November 12th.
On average, analysts expect that Interpace Diagnostics Group will report full year earnings of ($0.31) per share for the current fiscal year, with EPS estimates ranging from ($0.32) to ($0.29). For the next year, analysts anticipate that the company will post earnings of ($0.16) per share, with EPS estimates ranging from ($0.20) to ($0.12). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Interpace Diagnostics Group.
Interpace Diagnostics Group (NASDAQ:IDXG) last released its quarterly earnings results on Thursday, August 9th. The business services provider reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. Interpace Diagnostics Group had a negative return on equity of 34.58% and a negative net margin of 71.14%. The firm had revenue of $5.50 million for the quarter, compared to the consensus estimate of $4.80 million.
Shares of IDXG traded up $0.02 during midday trading on Wednesday, hitting $1.41. The stock had a trading volume of 340,117 shares, compared to its average volume of 489,687. Interpace Diagnostics Group has a twelve month low of $0.77 and a twelve month high of $1.78. The company has a market capitalization of $38.60 million, a price-to-earnings ratio of -1.79 and a beta of 2.26.
Several large investors have recently added to or reduced their stakes in IDXG. JPMorgan Chase & Co. acquired a new stake in shares of Interpace Diagnostics Group in the third quarter valued at about $194,000. Essex Investment Management Co. LLC acquired a new stake in shares of Interpace Diagnostics Group in the third quarter valued at about $465,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of Interpace Diagnostics Group in the third quarter valued at about $983,000. 15.59% of the stock is currently owned by institutional investors and hedge funds.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Further Reading: What are trading strategies for the 52-week high/low?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.